logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
07/09/2025
Airbus: Delivered 114 A320neo aircraft from January to August.
Latest
14 m ago
On September 7th, Kangfang Biotech announced updated data from the first global multicenter Phase III clinical trial HARMONi of Ivosidenib (AK112) at the World Lung Cancer Congress. The study evaluated the efficacy and safety of Ivosidenib combined with chemotherapy in patients with disease progression after third-generation EGFR-TKI treatment. Results showed that the median follow-up time was 13.7 months, and the overall survival (OS) data significantly improved survival benefits in the North American population. Ivosidenib is the world's first PD-1/VEGF dual-antibody drug. In last year's domestic registration Phase III clinical trial (HARMONi-2) for first-line treatment of PD-L1-positive non-small cell lung cancer, Ivosidenib showed the potential to replace the PD-1 inhibitor Pembrolizumab (known as "Keytruda") with longer progression-free survival (PFS). Ivosidenib has gained fame as the hottest dual-antibody globally. (Daily Economic News)
14 m ago
Kangfang Biological first global multicenter phase III clinical study results announced: has reached the primary endpoint.
26 m ago
The 12th World Chinese Media Forum is held in Kunming.
29 m ago
Pay attention to preventing and guarding against the pre-release of the Shenzhen District Typhoon Yellow Alert Signal.
34 m ago
US Poll: Trump's approval rating is 43%, inflation handling approval rating is the lowest.
See all latestmore
logo
Contact US
qr
+852 - 60190728
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.